Skip to content

Probiotic Intervention for Gut Function

A Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate the Effect of Probiotics on Gut Function in Healthy Chinese Adults

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05155449
Enrollment
200
Registered
2021-12-13
Start date
2023-02-08
Completion date
2024-06-03
Last updated
2025-06-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gut Function

Brief summary

The effect of probiotics on gut function in healthy subjects.

Interventions

DIETARY_SUPPLEMENTProbiotics

Capsule

DIETARY_SUPPLEMENTPlacebo

Capsule

Sponsors

Probi AB
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

* Age between 18 and 65 years * BMI between 18.5 and 27.9 kg/m² * Subjects having ≥ 3 bowel movements per day * Subject not satisfied with their bowel habits * Subject having frequent stools during more than 4 weeks * For women: Non menopausal with the same reliable contraception since at least 3 cycles before the beginning of the study and agreeing to keep it during the entire duration of the study * Subjects agreeing to keep their dietary and life habits unchanged throughout the study * Good general and mental health within the opinion of the investigator * Able and willing to participate to the study by complying with the protocol procedures as evidenced by a dated and signed ICF

Exclusion criteria

* Suffering IBS according to Rome IV criteria, chronic intestinal disease, immunodeficiency disorder or immunosuppressive treatment * Clinically significant frequent constipation or diarrhea at the screening visit as judged by the Investigator * Suffering from a severe chronic disease or GI disorders found to be inconsistent with the conduct of the study by the investigator * Intake of antibiotics within 8 weeks prior to the start of the study * With regular intake of probiotics within four weeks prior to V1 visit * Under treatment or dietary supplement which could significantly affect parameter(s) followed during the study according to the investigator or stopped in a too short period before the V1 visit * Suspected alcohol or substance abuse * Use of medications other than contraceptives or prescribed medication after consulting with the investigator * History of any clinically significant disease or disorder which, in the opinion of the Investigator, may either put the subject at risk if participating in the study, or influence the results or the subject´s ability to participate in the study * With a known gluten intolerance, milk protein allergy * With a known or suspected food allergy or intolerance or hypersensitivity to any of the study products' ingredients * Pregnant or lactating women or intending to become pregnant within 3 months ahead * With significant change in food habits or in physical activity in the 3 months before the V1 visit * With a personal history of anorexia nervosa, bulimia or significant eating disorders according to the investigator * Having a lifestyle deemed incompatible with the study according to the investigator * Currently participating in another clinical study, has done so in the past 30 days or being in the exclusion period of a previous clinical trial * Under legal protection (guardianship, wardship) or deprived from his/her rights following administrative or judicial decision * Presenting a psychological or linguistic incapability to sign the informed consent or Investigator considers the subject unlikely to comply with study procedures, restrictions and requirements * Impossible to contact in case of emergency

Design outcomes

Primary

MeasureTime frameDescription
Bowel movements8 weeksReduction of the number of bowel movements

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026